Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach

The treatment of HR+/HER2- metastatic breast cancer with cyclin-dependent kinases 4 and 6 inhibitors combined with endocrine therapy has recently emerged as the most relevant therapeutic strategy. However, in routine clinical practice, the best therapeutic approach in patients with comorbidities at...

Descripción completa

Detalles Bibliográficos
Autores principales: Fabi, Alessandra, Buono, Giuseppe, Bria, Emilio, Bianchini, Giampaolo, Curigliano, Giuseppe, De Laurentiis, Michelino, De Placido, Sabino, Del Mastro, Lucia, Guarneri, Valentina, Generali, Daniele, Livi, Lorenzo, Lorusso, Vito, Montemurro, Filippo, Puglisi, Fabio, Vigneri, Paolo, Zambelli, Alberto, Arpino, Grazia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501706/
https://www.ncbi.nlm.nih.gov/pubmed/36158652
http://dx.doi.org/10.3389/fonc.2022.950861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501706/
https://www.ncbi.nlm.nih.gov/pubmed/36158652
http://dx.doi.org/10.3389/fonc.2022.950861

Ejemplares similares